We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Test Authorized to Identify Candida auris

By LabMedica International staff writers
Posted on 30 Apr 2018
Print article
Image: A strain of Candida auris cultured in a petri dish. C. auris is difficult to identify with standard laboratory methods, and can be misidentified in laboratories without specific technology (Photo courtesy of the CDC).
Image: A strain of Candida auris cultured in a petri dish. C. auris is difficult to identify with standard laboratory methods, and can be misidentified in laboratories without specific technology (Photo courtesy of the CDC).
Candida auris is a yeast that can cause serious infections in hospitalized patients such as bloodstream infections and is frequently resistant to multiple antifungal drugs used to treat Candida infections. The US Administration has authorized the first test to identify the emerging pathogen (C. auris), which can cause serious infections in hospitalized patients.

Specifically, the US Food and Drug Administration (FDA, Silver Springs, MD, USA) permitted marketing for a new use of the BRUKER MALDI Biotyper CA system (Bruker Daltonik GmbH, Bremen, Germany) for the identification of C. auris, adding to the system’s already cleared uses for the identification of 333 species or species groups, covering 424 clinically relevant bacteria and yeast species.

The FDA evaluated the use of a standard protocol for adding C. auris to the BRUKER MALDI Biotyper CA system database in conjunction with the performance data of 28 C. auris isolates (samples) and other supporting analytical studies. Findings indicated that the system can reliably identify C. auris 100% of the time. Risks associated with use of the system may include no identification or misidentification of a microorganism. C. auris isolates were obtained from various culture collections.

In addition, the FDA plans to propose to exempt certain mass spectrometry microorganism identification system processes from an additional premarket review after a system process receives a first-time FDA marketing authorization (e.g., 510(k) clearance). A proposed exemption of this kind would further meet the need for updates to device-specific organism databases and enable these mass spectrometry devices to expand their microorganism identification capabilities in the least burdensome manner.

Donald St. Pierre, acting director of the Office of In Vitro Diagnostics and Radiological Health in the FDA, said, “Although mass spectrometry technology has been a powerful scientific tool since the 1980s, it is only within that the last five years that it has been effectively used for the identification of microbiological organisms and is now a widely recognized standard of practice for clinical laboratories. The FDA has confidence in this technology and recognizes the need to rapidly address outbreaks both for C. auris and for other pathogenic microorganisms to help protect Americans through the recognition and identification of emerging infectious pathogens.”

Related Links:
US Food and Drug Administration
Bruker Daltonik

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.